Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:

NCT ID: NCT06251947 Recruiting - Ovarian Cancer Clinical Trials

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).

NCT ID: NCT06251388 Recruiting - Cervical Cancer Clinical Trials

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab(AK104) for Newly Diagnosed Local Advanced Cervical Cancer

Start date: February 20, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of concurrent chemoradiotherapy(CCRT)followed by cadonilimab(AK104) in high risk local advanced cervical cancer. Participants received CCRT,efficacy evaluation of CCRT was no disease progression who maintained with AK104(10.0 mg/kg,Q3W)until drug exposure over 1 years or disease progression or intolerable toxicity.

NCT ID: NCT06241781 Not yet recruiting - Adult Clinical Trials

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.

NCT ID: NCT06238635 Recruiting - Cervical Cancer Clinical Trials

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Start date: March 11, 2024
Phase: Phase 2
Study type: Interventional

This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

NCT ID: NCT06238284 Not yet recruiting - Ovarian Cancer Clinical Trials

HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China

Start date: January 26, 2024
Phase:
Study type: Observational

This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.

NCT ID: NCT06237257 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

The Primary purpose of this study is to evaluate the safety of SHR-1316 plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The second purpose of this study is to evaluate the efficacy and PK traits; The exploratory study is to explore the biomarker 、immunogenicity and so on .

NCT ID: NCT06232083 Recruiting - Immunotherapy Clinical Trials

Application of PLDR External Irradiation Combined With Immune Checkpoint Inhibitors in Recurrent Cervical Cancer

Start date: February 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

At present, the treatment methods for recurrent cervical cancer are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent cervical cancer, but the clinical response rate is insufficient. Pulse low-dose rate radiotherapy (PLDR) is a new technology in recent years, which uses continuous pulse low-dose rate irradiation to induce hypersensitivity in tumors, and its clinical safety has been verified. Compared to conventional radiotherapy, PLDR has advantages in protecting the lymphatic system and relieving the immune barrier, but it is still unclear whether it can improve the efficacy of ICB. This project aims to combine PLDR with ICB to explore new strategies for recurrent cervical cancer.

NCT ID: NCT06229275 Not yet recruiting - Clinical trials for Cervical Cancer Screening

Study to Evaluate the Effectiveness of the Personal Pap Smear Device™ for Collection of Cervical Cells

Start date: February 2, 2024
Phase: Phase 3
Study type: Interventional

This purpose of this research study is to determine the effectiveness of the Personal Pap Smear TM Device to collect adequate cervical cell samples for cytology examination when compared with the Rover Cervex-Brush (Cervix-Examination Brush).

NCT ID: NCT06226350 Completed - Cervical Cancer Clinical Trials

A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma

Start date: March 4, 2021
Phase: Phase 2
Study type: Interventional

This study was an open, single-arm, enriched, multicenter Phase II study.

NCT ID: NCT06223308 Recruiting - Cervical Cancer Clinical Trials

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

Start date: September 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

It is a phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors.